Conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration Age-related Macular Degeneration
Keywords: AMD macular degeneration Everolimus Lucentis Ranibizumab Choroidal Neo-Vascular (CNV) age-onset macular degeneration Age-related Macular Degeneration (AMD)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: no

Brief summary:
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)

Detailed description:

Arms:
arm 1: 5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28 arm 2: Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline) arm 3: Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)

Interventions: intervention 1: Everolimus intervention 2: Ranibizumab
Intervention descriptions: intervention 1: 5 mg oral tablet intervention 2: 0.5 mg administered by intravitreal injection

Protocol document: